|
|
| Research article summary (published 29 Jun 2006): |
Drug insight: Clopidogrel nonresponsiveness.
Full Abstract
Platelet reactivity to agonists and subsequent activation are important factors that affect the development of atherothrombosis and resultant ischemic events. Pharmacologic intervention with clopidogrel and aspirin during acute coronary syndromes and percutaneous coronary intervention is considered the gold standard for attenuating platelet activation and aggregation. Despite significant benefits reported with dual antiplatelet treatment in major clinical trials, the occurrence of adverse ischemic events, including stent thrombosis, remains a serious clinical problem. Nonresponsiveness, also called resistance, to current clopidogrel regimens might play a part in the occurrence of ischemic events. Various mechanisms have been implicated in nonresponsiveness to clopidogrel, including variability in intestinal absorption and hepatic conversion to the active metabolite, drug-drug interactions and receptor polymorphisms. Increased loading and maintenance doses and the use of new and more-potent P2Y12-receptor blockers might overcome the phenomenon of clopidogrel nonresponsiveness. The aim of this article is to provide a comprehensive and current review of clopidogrel response variability and nonresponsiveness.
Author information
Author/s: Gurbel, Paul A (PA); Tantry, Udaya S (US);
Affiliation: Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA. pgurbel(-atsign-)lifebridgehealth.org
Journal and publication information
Publication Type: Journal Article; Review
Journal: Nature clinical practice. Cardiovascular medicine (Nat Clin Pract Cardiovasc Med), published in England. (Language: eng)
Reference: 2006-Jul; vol 3 (issue 7) : pp 387-95
Dates: Created 2006/06/30; Completed 2006/11/21;
PMID: 16810174, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Response to letter of Dr van Werkum et al.
6 Mar 2007 - Clopidogrel resistance--the cardiologist's perspective.
29 Apr 2007 - Overcoming "resistance" to aspirin and clopidogrel with tirofiban: fact or fiction?
29 Sep 2008 - [Pharmacology of ticlopidine and clopidogrel in comparison with acetylsalicylic acid]
30 Oct 1997 - What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?
29 Nov 2005 - Thrombogenesis and inhibition of platelet aggregation. Experimental aspects and future approaches.
30 Dec 1989 - Role of clopidogrel in managing atherothrombotic cardiovascular disease.
18 Mar 2007 - [Methods to evaluate aspirin and clopidogrel resistance]
30 Jan 2008 - Polypharmacologic interactions in the management of thrombosis.
30 Mar 1989 - [Resistance to acetylsalicylic acid and clopidogrel: current status]
30 Jul 2006
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.